Shining on Major News: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Transgenomic Inc. (NASDAQ:TBIO), Riverview Bancorp Inc. (NASDAQ:RVSB), MFA Financial, Inc. (NYSE:MFA), Civeo Corporation (NYSE:CVEO)

Vetr lowered shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a buy rating to a hold ratingin a research report report published onMonday, Analyst Ratings reports. The firm currently has $14.00 price target on the biotechnology company’s stock. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) belongs to Healthcare sector. Its weekly performance is -21.49%. On last trading day company shares ended up $10.52. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) distance from 50-day simple moving average (SMA50) is -10.13%.

Transgenomic, Inc. (NASDAQ: TBIO) announced that it has established a Clinical-Commercial Advisory Board (CCAB) for oncology applications of its Multiplexed ICE COLD-PCRTM (MX-ICP) technology. The CCAB is headed by Dr. Scott Patterson, a recognized expert in the application of genetic biomarkers to cancer drug development. Transgenomic Inc. (NASDAQ:TBIO) shares moved up 5.65% in last trading session and ended the day at $1.31. TBIO Gross Margin is 37.40% and its return on assets is -44.30%. Transgenomic Inc. (NASDAQ:TBIO) quarterly performance is -16.56%.

On 11 August, Riverview Bancorp Inc. (NASDAQ:RVSB) shares moved down -0.70% and was closed at $4.27. RVSB EPS growth in last 5 year was 19.10%. Riverview Bancorp Inc. (NASDAQ:RVSB) year to date (YTD) performance is -4.69%.

On 4 August, MFA Financial, Inc. (NYSE: MFA) announced financial results for the second quarter ended June 30, 2015. In the second quarter, both net income and dividend per common share were $0.20. Net income of $74.3 million includes $7.6 million of gains realized on sales of MBS. MFA Financial, Inc. (NYSE:MFA) ended the last trading day at $7.43. Company weekly volatility is calculated as 1.36% and price to cash ratio as 12.60. MFA Financial, Inc. (NYSE:MFA) showed a weekly performance of -0.80%.

On 30 July, Civeo Corporation (NYSE:CVEO) generated revenues of $143.1 million, EBITDA of $28.8 million and Adjusted EBITDA of $40.7 million. Net loss for the quarter was $13.5 million, or $0.13 per diluted share, inclusive of a $6.6 million (or $0.06 per diluted share) after-tax loss related to the impairment of fixed assets at a village in Australia and a $1.6 million (or $0.02 per diluted share) after-tax loss from costs incurred in connection with the migration to Canada. Civeo Corporation (NYSE:CVEO) shares moved down -6.22% in last trading session and ended the day at $1.81. CVEO Gross Margin is 40.80% and its return on assets is -13.60%. Civeo Corporation (NYSE:CVEO) quarterly performance is -59.96%.

Leave a Reply

Your email address will not be published. Required fields are marked *